Medtronic announces data from CoreValve ADVANCE Study & Symplicity HTN-1 (MDT) 42.00 : Co announced new findings from the Medtronic CoreValve ADVANCE Study for 1-year survival and health-related quality of life (HRQoL). The findings were presented this week at Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2012 in Miami. Initial 1-year results of the ADVANCE Study revealed that patients experienced high survival rates, with 1-year survival at 82.1 percent and 1-year cardiovascular survival at 88.2 percent. Health-related quality of life (HRQoL) measures for patients in the ADVANCE Study improved significantly at 1 and 6 months, compared with their status prior to receiving the Medtronic CoreValve System.

Co also announced new results from Symplicity HTN-1, the longest running clinical trial investigating the safety and efficacy of renal denervation. These data showed patients who received renal denervation treatment with the Symplicity system experienced a mean blood pressure reduction of -29/-14 mm Hg [p<0.01] at 24 months (n=105). These data expand the total number of patients to nearly two times the number previously reported at 24 months (n=59) from this clinical trial. The safety of renal denervation with the Symplicity system was also maintained at 24 months.